Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.

Aug 21, 2024 - 06:00

0 4

Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result

CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.

Tags:

Previous Article

Medtronic CEO: Strong single-digit earnings ahead as forex impact fades in the s...

SEC approves tougher rules around auditor 'negligence'

admin

admin

This website uses cookies to enhance your browsing experience. By continuing to use this site, you consent to the use of cookies. Please review our Privacy Policy for more information on how we handle your data.